Do You Believe in Merck & Co.’s (MRK) Upside Potential?

3 days ago 4

Soumya Eswaran

Fri, November 14, 2025 astatine 7:24 AM CST 3 min read

Antipodes Partners precocious published its “Antipodes Global Value Strategy” third-quarter 2025 capitalist letter, highlighting the cardinal show stocks, portfolio changes, and the marketplace outlook. A transcript of the missive tin beryllium downloaded here. In the quarter, planetary equities roseate positively, supported by easing commercialized tensions, excitement astir AI, and expectations of complaint cuts by the Federal Reserve. Global equities gained +7.6% successful USD and +6.4% successful AUD, driven by cardinal slope involvement complaint reductions, caller US commercialized agreements, and beardown firm earnings. The Antipodes Global Value Strategy outperformed the benchmark during this 4th and showed adjacent greater outperformance for the twelvemonth to day and the 12 months ending September 30, 2025. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Antipodes Global Value Strategy highlighted stocks specified arsenic Merck & Co., Inc. (NYSE:MRK). Headquartered successful Rahway, New Jersey, Merck & Co., Inc. (NYSE:MRK) is simply a starring healthcare company. The one-month instrumentality of Merck & Co., Inc. (NYSE:MRK) was 9.60%, and its shares mislaid 3.51% of their worth implicit the past 52 weeks. On November 13, 2025, Merck & Co., Inc. (NYSE:MRK) banal closed astatine $92.93 per share, with a marketplace capitalization of $230.654 billion.

Antipodes Global Value Strategy stated the pursuing regarding Merck & Co., Inc. (NYSE:MRK) successful its 3rd 4th 2025 capitalist letter:

"Within healthcare, we accrued vulnerability via Merck & Co., Inc. (NYSE:MRK), arsenic the marketplace remains fixated connected the company’s quality to offset Keytruda’s patent cliff from precocious 2028. Our presumption remains that the company’s increasing pipeline should commencement delivering results implicit the adjacent 2 years which volition code the patent cliff arsenic good thrust valuation upside."

Why Merck & Co (MRK) Continues to Rank Among the Most Profitable Dividend Stocks

Merck & Co., Inc. (NYSE:MRK) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 92 hedge money portfolios held Merck & Co., Inc. (NYSE:MRK) astatine the extremity of the 2nd quarter, compared to 93 successful the erstwhile quarter. In Q3 2025, Merck & Co., Inc. (NYSE:MRK) reported revenues of $17.3 billion, marking an summation of 4% from Q3 2024. While we admit the imaginable of Merck & Co., Inc. (NYSE:MRK) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.